Day: November 15, 2020

MyoKardia Presents Cardiac Imaging Data from 30-Week EXPLORER-HCM Study of Mavacamten

EXPLORER-HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in CirculationMavacamten Treatment Resulted in Favorable Effect on Cardiac Structure — Significantly Reduced Hypertrophy in Patients with Hypertrophic CardiomyopathyBRISBANE, Calif., Nov. 15, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) announced results from its cardiac magnetic resonance imaging (CMR) substudy of mavacamten for the potential treatment of hypertrophic cardiomyopathy (HCM) showing that 30-week treatment with mavacamten has a favorable effect on cardiac structure, while maintaining contractile function within the normal range. These data were shared today in an oral presentation titled, “Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM CMR...

Continue reading

Arbutus Announces Presentation of Phase 1a/1b Clinical Trial Results for AB-729 in Chronic Hepatitis B Subjects at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting

Across all single-dose cohorts, mean HBsAg concentrations continuously declined up to week 12 before reaching a plateau, suggesting dosing of AB-729 less frequently than every 4 weeks may be warranted        In the 60 mg every 4 weeks multi-dose cohort, HBsAg concentrations continued to decline steadily beyond week 12 with no plateau in response observed to date          Both HBV RNA and HBcrAg concentrations declined after single- and multi-dose administration of AB-729          AB-729 was generally safe and well toleratedConference Call and Webcast Scheduled for Monday, November 16, 2020 at 8:00 am ETWARMINSTER, Pa., Nov. 15, 2020 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection...

Continue reading

Prologue – Chiffre d’affaires de 16,9 M€ au T3 2020 en baisse de -6,7%,croissance de toutes les activités hors formation

PROLOGUECHIFFRE D’AFFAIRES DE 16,9 M€ AU T3 2020 EN BAISSE DE -6,7% (-5,7% A CHANGE CONSTANT)CROISSANCE DE TOUTES LES ACTIVITÉS HORS FORMATIONCROISSANCE DES ACTIVITÉS CLOUD DE +12,6% (+20,0% À CHANGE CONSTANT)LINKBYNET INTÈGRE LA TECHNOLOGIE INVENTORY DE USE IT CLOUD À SA CMDBDÉBUT DE REBOND DE L’ACTIVITÉ FORMATION TOUJOURS MARQUÉE PAR LA CRISE SANITAIRE*(données non auditées)  ** (D à taux de change constant)CROISSANCE DE TOUTES LES ACTIVITÉS HORS FORMATIONLe groupe Prologue a enregistré au 3ème trimestre 2020 un chiffre d’affaires de 16,86 M€ en baisse de -6,7% (-5,7% à change constant). Hors activité de formation, la croissance du groupe atteint sur cette période +13,7% (à change constant).  CROISSANCE DE +12,6% (+20,0% A CHANGE CONTANT) DES ACTIVITÉS CLOUD ET SERVICES MANAGÉSL’activité Cloud et Services Managés a enregistré sur le...

Continue reading

RAPT Therapeutics to Announce Initial Data from Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2020 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that the Company plans to present initial data from its Phase 1/2 clinical trial of FLX475 in patients with multiple cancer indications in a premarket press release and webcast on Monday, November 16, 2020.RAPT will host a conference call accompanied by a slide presentation at 8:30 a.m. ET on Monday, November 16th. The live webcast and audio archive of the presentation may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations. The call can be accessed...

Continue reading